NCT06457464View on ClinicalTrials.gov

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

October 1, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Chemotherapy

combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)

All Listed Sponsors
lead

Assiut University

OTHER

NCT06457464 - Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter